Clinical Trial

An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
Multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety of study drug for the treatment of the MPS II.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-04-13; most recent amendment 2025-07-21.
Status change: Enrolling by Invitation → Active, Not Recruiting 2021-01-31
Trial Details
NCT Number NCT04348136
Lead Sponsor JCR Pharmaceuticals Co., Ltd.
Conditions Mucopolysaccharidosis II
Enrollment 27 participants
Start Date 2019-09-01
Primary Completion 2030-03-31 (estimated)
Study Completion 2030-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-24